

2-2-04



Docket No. MCP 5018

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : OLIVER B. ANDERSON, et al.

Serial No. : 10/677984 Art Unit: 3721

Filed : October 2, 2003 Examiner:

For : ZERO CYCLE MOLDING SYSTEMS, METHODS AND APPARATUSES FOR MANUFACTURING DOSAGE FORMS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 30, 2004

(Date of Deposit)

DAVID R. CRICHTON

(Name of applicant, assignee, or Registered Representative)


(Signature)

January 30, 2004

(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with the first or second After Final Submission, therefore:

- Statement in Accordance with §1.97(e)
(attached); or
- Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- Statement in Accordance with §1.97(e)
(attached); or
- Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).

In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
 - In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
 - If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
- Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

There are no listed references which are not in the English language.


The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/MCP5018/DRC. This form is submitted in triplicate.

Respectfully submitted,



DAVID R. CRICHTON

Reg. No. 37,300

Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6131
DATED: January 30, 2004



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		599,865		E. L. Richards	03/01/1898	
		2,307,371		H. B. Hileman	01/05/1943	
		3,146,169		D. Stephenson, et al.	08/25/1964	
		3,726,622		Georges D. DeTroyer et al.	04/10/1973	
		3,804,570		Gunter Hoschele et al.	04/16/1974	
		3,832,252		T. Higuchi, et al.	10/02/1972	
		4,139,589		Monique Beringer, et al.	02/13/1979	
		4,173,626		Robert E. Dempski, et al.	11/06/1979	
		4,230,693		Henry J. Izzo, et al.	10/28/1980	
		4,271,206		Harry F. Fariel, et al.	06/02/1981	
		4,273,793		Harry F. Fariel, et al.	06/16/1981	
		4,292,017		Wallace A. Doepel	09/29/1981	
		4,362,757		Andy C. C. Chen, et al.	12/07/1982	
		4,371,516		George K. E. Gregory, et al.	02/01/1983	
		4,372,942		Paul A. Cimiluca	02/08/1983	
		4,425,332		Michael H. James	01/10/1984	
		4,473,526		Eugen Buhler et al.	09/25/1984	
		4,518,335		Vimal K. Pujari	05/21/1985	
		4,544,345		Eugen Buhler et al.	10/01/1985	
		4,569,650		Hans Kramer	02/11/1986	
		4,576,284		Fritz Wittwer, et al.	03/18/1986	
		4,686,212		Fred P. Ducatman, et al.	08/11/1987	
		4,738,817		Fritz Wittwer, et al.	04/19/1988	
		4,749,575		Avner Rotman	06/07/1988	
		4,757,090		Anil M. Salpekar, et al.	07/12/1988	
		4,762,719		Mark Forester	08/09/1988	
		4,781,714		J. B. Eckenhoff et al.	11/01/1988	
		4,813,818		Michael Sanzone	3/21/1989	
		4,820,524		Norbert I. Berta	04/11/1989	
		4,851,226		Thomas N. Julian, et al.	07/25/1989	
		4,863,742		Donald E. Panoz, et al.	09/05/1989	
		4,882,167		Choong-Gook Jang	11/21/1989	



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

<i>Application Number</i>	10/677984
<i>Filing Date</i>	October 2, 2003
<i>First Named Inventor</i>	Oliver B. Anderson
<i>Group Art Unit</i>	3721
<i>Examiner Name</i>	Not yet assigned
<i>Attorney Docket Number</i>	MCP 5018

		4,906,478		William Valentine, et al.	03/06/1990	
		4,929,446		Raymond A. Bartolucci	05/29/1990	
		4,965,027		Nobuyuki Takahashi	10/23/1990	
		4,980,169		Alfred Oppenheimer, et al.	12/25/1990	
		4,980,170		Gerhard Schneider, et al.	12/25/1990	
		5,002,970		George A. Eby, III	03/26/1991	
		5,059,112		Marianne Wieser	10/22/1991	
		5,075,114		Edward J. Roche	12/24/1991	
		5,089,270		Douglas B. Hampton et al.	02/18/1992	
		5,146,730		Hani Sadek et al.	09/15/1992	
		5,200,191		Don Steele et al.	04/06/1993	
		5,213,738		Douglas B. Hampton et al.	05/25/1993	
		5,213,808		Daniel Bar-Shalom, et al.	05/25/1993	
		5,228,916		Norbert I. Berta	07/20/1993	
		5,229,164		Heinrich Pins, et al.	07/20/1993	
		5,275,822		William Valentine, et al.	01/04/1994	
		5,286,497		Dennis L. Hendrickson, et al.	02/15/1994	
		5,368,863		James B. Eckenhoff, et al.	11/29/1994	
		5,391,378		Richard Sanderson	02/21/1995	
		5,405,642		Paul M. V. Gilis, et al.	04/11/1995	
		5,415,868		Floyd S. Smith et al.	05/16/1995	
		5,436,026		Norbert I. Berta	07/25/1995	
		5,459,983		Hani Sadek et al.	10/24/1995	
		5,464,631		Charles E. Hoover et al.	11/07/1995	
		5,489,436		Michael R. Hoy, et al.	02/06/1996	
		5,511,361		Erich W. Sauter	04/30/1996	
		5,538,125		Norbert I. Berta	07/23/1996	
		5,578,336		Woodrow C. Monte	11/26/1996	
		5,609,010		Erich W. Sauter	03/11/1997	
		5,614,207		Manoj N. Shah	03/25/1997	
		5,679,406		Norbert I. Berta	10/21/1997	
		5,681,584		Louis Savastano, et al.	10/28/1997	
		5,795,588		Erich W. Sauter	08/18/1998	
		5,824,338		Richard L. Jacobs et al.	10/20/1998	
		5,830,501		Liang C. Dong et al.	11/03/1998	
		5,830,502		Liang C. Dong et al.	11/03/1998	




Substitute for form 1449, PATENT TRADEMARK OFFICE		<i>Application Number</i>	10/677984
		<i>Filing Date</i>	October 2, 2003
		<i>First Named Inventor</i>	Oliver B. Anderson
		<i>Group Art Unit</i>	3721
		<i>Examiner Name</i>	Not yet assigned
		<i>Attorney Docket Number</i>	MCP 5018

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

	5,834,035		Michio Osada et al.	11/10/1998
	5,837,301		Robin A. Arnott et al.	11/17/1998
	5,853,760		Karsten Cremer	12/29/1998
	5,871,781		Garry L. Myers, et al.	02/16/1999
	5,912,013		Edward M. Rudnic, et al.	06/15/1999
	5,942,034		Jeffrey D. Brehant et al.	08/24/1999
	5,997,905		Daniel McTeigue, et al.	12/07/1999
	6,001,391		Jurgen Zeidler, et al.	12/14/1999
	6,103,257		Keith Nisonoff	08/15/2000
	6,103,260		Joseph R. Luber, et al.	08/15/2000
	6,117,479		John E. Hogan et al.	09/12/2000
	6,149,939		Mathew A. Strumor, et al.	11/21/2000
	6,149,943		Daniel McTeigue, et al.	11/21/2000
	6,200,590	B1	John Graham Eley	03/13/2001
	6,248,760	B1	Paul C. Wilhelmsen	06/19/2001
	6,270,805	B1	Chih-Ming Chen, et al.	08/07/2001
	6,322,819	B1	Beth A. Burnside, et al.	11/27/2001
	6,350,398	B1	Jorg Breitenbach	02/26/2002
	6,365,185	B1	Wolfgang A. Ritschel	04/02/2002
	6,609,902	B1	Paul Richard Blais, et al.	08/26/2003
	2001/0001280	A1	Liang-Chang Dong, et al.	05/17/2001
	2002/0028240	A1	Toyohiro Sawada, et al.	03/07/2002
	2003/0068373	A1	Joseph Luber, et al.	04/10/2003



Substitute for form 1449 (1-2001)			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 4 of 6			
		Application Number	10/677984
		Filing Date	October 2, 2003
		First Named Inventor	Oliver B. Anderson
		Group Art Unit	3721
		Examiner Name	Not yet assigned
		Attorney Docket Number	MCP 5018

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		DE	27 10 307		Verfahren zur Herstellung von Verpackung von festen pharmazeutischen Doseinheiten (English abstract attached)	09-15-1977		
		EP	0 088 556	B1	Sumitomo Chemical Company Ltd.	09-14-1983		
		EP	0 239 983	B1	Boehringer Ingelheim International GmbH (English abstract attached)	10-07-1987		
		EP	0 294 993	B1	Pfizer Inc.	12-14-1991		
		EP	0 481 547	A1	Unilever PLC	04-22-1992		
		EP	0 788 790	A2	Jagotec AG	02-06-1996		
		EP	0 861 659	A1	University of Kentucky Research Foundation	02-21-1992		
		EP	0 950 402	B1	McNeil-PPC, Inc.	02-22-1999		
		EP	1 077 065	A1	Chugai Seiyaku Kabushiki Kaisha	02-21-2001		
		FR	2 604 904		Alza Corporation	10-13-1986		
		GB	759 081		John Holroyd & Company, et al.	10-10-1956		
		GB	888 038		The Wander Company	01-24-1962		
		GB	936 386		The Wellcome Foundation Limited	09-11-1963		
		GB	994 742		The Wellcome Foundation Limited	06-10-1965		
		GB	1 144 915		Armour Pharmaceutical Company	03-12-1969		
		GB	1 372 040		Boehringer Ingelheim	10-30-1974		
		GB	2 197 778	A	Katjes Fassin GmbH & Co. KG	06-02-1988		
		NL	8602556		Alza Corporation	10-10-1986		
		WO	94/06416	A1	Ubaldo Conte et al.	03-31-1994		
		WO	94/07470		Pfizer, Inc.	04-14-1994		
		WO	95/02396	A1	SmithKline Beecham Corporation	01-26-1995		
		WO	97/06695	A1	The Procter & Gamble Company	02-27-1997		
		WO	99/02136		Peter Greither (English abstract attached)	01-21-1999		
		WO	99/51209	A1	Impax Pharmaceuticals, Inc.	10-14-1999		
		WO	99/56730		Alza Corporation	11-11-1999		
		WO	00/18447	A2	Impax Pharmaceuticals, Inc.	04-06-2000		
		WO	00/25755		Fuisz Technologies Ltd.	05/11/2000		
		WO	01/15889	A1	Gunter M. Voss (English abstract attached)	03/08/2001		
		WO	03/020246	A1	SmithKline BeechamPLC	03/13/2003		
		WO	03/028619	A2	McNeil-PPC, Inc.	04-10-2003		



Substitute for form 1449-A PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

<i>Application Number</i>	10/677984
<i>Filing Date</i>	October 2, 2003
<i>First Named Inventor</i>	Oliver B. Anderson
<i>Group Art Unit</i>	3721
<i>Examiner Name</i>	Not yet assigned
<i>Attorney Docket Number</i>	MCP 5018

WO 03/028990 A1 McNeil-PPC, Inc.

04-10-2003

		WO	03/028990	A1	McNeil-PPC, Inc.	04-10-2003		
--	--	----	-----------	----	------------------	------------	--	--

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached *Kinds of U.S. Patent Documents*. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

Substitute for form 1449A/PTO		Application Number	10/677984
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	October 2, 2003
(use as many sheets as necessary)		First Named Inventor	Oliver B. ANDerson
Sheet 6 of 6		Group Art Unit	3721
		Examiner Name	Not yet assigned
		Attorney Docket Number	MCP 5018

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.